Phase Ib/II Results for TP53-Mutant MDS and AML
David Sallman, MD, assistant member, Department of Malignant Hematology, Moffitt Cancer Center, explains the significance of the initial results from a recent phase 1B/2 trial combining APR-246 and azacitidine (Vidaza) in patients with TP53-mutant myelodysplastic syndrome and acute myeloid leukemia.
David Sallman, MD, assistant member, Department of Malignant Hematology, Moffitt Cancer Center, explains the significance of the initial results from a recent phase Ib/II trial combining APR-246 and azacitidine (Vidaza) in patients with TP53-mutant myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).
Out of 12 patients enrolled in the trial, 9 patients were found evaluable. Eight of these patients had achieved complete remission, Sallman said.
